Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Sponsors and Collaborators
Southwest Oncology Group
Click here and scroll down to view study contact and location info
Mikkael A. Sekeres, MD, MS
The Cleveland Clinic
Next post in Myelodysplasia Clinical Trials
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Want to read more?
Please login or register first to view this content.